CR HOLDINGS(01911),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

01911 CR HOLDINGS

Trading 01-22 13:47:52

4.220

-0.120

-2.76%

High4.410	Low4.180	Vol738.80K
Open4.350	D1 Closing4.340	Amplitude5.30%
Mkt Cap2.42B	Tradable Cap2.42B	Total Shares573.00M
T/O3.16M	T/O Rate0.13%	Tradable Shares573.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"01911","market":"HK","secType":"STK","nameCN":"CR HOLDINGS","latestPrice":4.22,"timestamp":1769060270964,"preClose":4.34,"halted":0,"volume":738800,"delay":0,"changeRate":-0.027649769585253482,"floatShares":573000000,"shares":573000000,"eps":-0.349837,"marketStatus":"Trading","change":-0.12,"latestTime":"01-22 13:47:52","open":4.35,"high":4.41,"low":4.18,"amount":3160469,"amplitude":0.052995,"askPrice":4.22,"askSize":9700,"bidPrice":4.21,"bidSize":700,"shortable":3,"etf":0,"ttmEps":-0.077,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1769069400000},"marketStatusCode":2,"adr":0,"listingDate":1537977600000,"exchange":"SEHK","adjPreClose":4.34,"openAndCloseTimeList":[[1769045400000,1769054400000],[1769058000000,1769068800000]],"volumeRatio":1.088524,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01911/tweets","defaultTab":"tweets","newsList":[{"id":"2602311894","title":"Innovent Biologics Reports Positive Phase 1b Results for IBI324 in Eye Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2602311894","media":"Reuters","labels":["productRelease","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602311894?lang=en_us&edition=fundamental","pubTime":"2026-01-09 08:00","pubTimestamp":1767916821,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc., in collaboration with its partner Ollin Biosciences, has announced positive topline results from the randomized, head-to-head Phase 1b JADE clinical study. The study compared IBI324 , a next-generation VEGF/Ang2 bispecific antibody, to faricimab  in over 160 patients with diabetic macular edema  or wet age-related macular degeneration . According to the announcement, OLN324 demonstrated superior outcomes and is characterized by higher anti-Ang2 potency and a differentiated profile for first-line standard of care. Full results from the JADE study are scheduled to be presented at the Angiogenesis, Exudation, and Degeneration 2026 symposium on February 7, 2026. Innovent and Ollin plan to advance OLN324 into global Phase 3 studies for both DME and wAMD.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDL1BjwzH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","LU0455707207.USD","LU2097828631.EUR","BK1583","01911","LU2242644610.SGD","LU2097828557.USD","LU2488822045.USD","LU2097828474.EUR","BK1161","BK1147","LU1969619763.USD","LU2328871848.SGD","LU2097828805.USD","LU0502904849.HKD","HK0000165453.HKD","01801","LU2097828714.EUR"],"gpt_icon":0},{"id":"2601433466","title":"China Renaissance Holdings Insiders Made A Wise Decision By Selling CN¥7.5m Worth Of Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2601433466","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601433466?lang=en_us&edition=fundamental","pubTime":"2026-01-08 07:51","pubTimestamp":1767829875,"startTime":"0","endTime":"0","summary":"While China Renaissance Holdings Limited ( HKG:1911 ) shareholders have enjoyed a good week with stock up 14%, they...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/7132000-choice2-main-header/1585186691278","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/7132000-choice2-main-header/1585186691278"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/diversified-financials/hkg-1911/china-renaissance-holdings-shares/news/china-renaissance-holdings-insiders-made-a-wise-decision-by-2","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/diversified-financials/hkg-1911/china-renaissance-holdings-shares/news/china-renaissance-holdings-insiders-made-a-wise-decision-by-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["01911","BK1147","CN"],"gpt_icon":0},{"id":"2595877264","title":"China Renaissance - Distressed Assets Portfolio I Are Non-Performing Personal Consumer Debts Owed to Fuzhou Qifu Financing Guarantee","url":"https://stock-news.laohu8.com/highlight/detail?id=2595877264","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595877264?lang=en_us&edition=fundamental","pubTime":"2025-12-31 22:01","pubTimestamp":1767189715,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nFWN3Y108S:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1147","01911"],"gpt_icon":0},{"id":"2595772574","title":"China Renaissance - Unit Buys Distressed Assets Portfolio I for RMB277.1 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2595772574","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595772574?lang=en_us&edition=fundamental","pubTime":"2025-12-31 22:01","pubTimestamp":1767189715,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nFWN3Y108S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1147","01911"],"gpt_icon":0},{"id":"2595772501","title":"China Renaissance Acquires Distressed Assets in Discloseable Transaction","url":"https://stock-news.laohu8.com/highlight/detail?id=2595772501","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595772501?lang=en_us&edition=fundamental","pubTime":"2025-12-31 22:01","pubTimestamp":1767189683,"startTime":"0","endTime":"0","summary":"China Renaissance Holdings Ltd. announced that its wholly-owned subsidiary entered into agreements to acquire two portfolios of distressed assets. The acquisitions, valued at approximately RMB277.1 million and RMB31.2 million respectively, are considered discloseable transactions under Hong Kong Listing Rules, requiring an announcement but not shareholders' approval.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Renaissance Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 31, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nNDL7QXJ4v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1147","01911"],"gpt_icon":0},{"id":"2595274950","title":"Innovent Biologics Gains China Approval for TABOSUN and Sintilimab in Colon Cancer Neoadjuvant Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2595274950","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595274950?lang=en_us&edition=fundamental","pubTime":"2025-12-29 07:30","pubTimestamp":1766964633,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc. announced that China's National Medical Products Administration has approved the New Drug Application for TABOSUN  in combination with sintilimab as a neoadjuvant treatment for stage IIB-III resectable microsatellite instability-high  or mismatch repair deficient colon cancer. The approval is based on interim analysis from the NeoShot trial, which showed a pathological complete response rate of 82% among the first 50 patients treated, without significant safety risks compared to direct surgery.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251228:nNDL2f1t1D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828474.EUR","LU2328871848.SGD","LU2097828714.EUR","LU0502904849.HKD","LU0455707207.USD","01801","LU2242644610.SGD","BK1583","LU2097828557.USD","LU2097828631.EUR","01911","BK1161","HK0000165453.HKD","LU1969619763.USD","BK1589","LU2097828805.USD","LU2488822045.USD","BK1147"],"gpt_icon":0},{"id":"2594233216","title":"Innovent Biologics Wins NMPA Approval for First Domestic CTLA-4 Antibody TABOSUN in Colon Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2594233216","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594233216?lang=en_us&edition=fundamental","pubTime":"2025-12-25 16:45","pubTimestamp":1766652331,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc. has received regulatory approval from China's National Medical Products Administration  for TABOSUN , the first domestic cytotoxic lymphocyte-associated antigen-4  monoclonal antibody. The approval is for use in combination with TYVYT  as a neoadjuvant treatment for patients with stage IIB-III resectable microsatellite instability-high or mismatch repair deficient  colon cancer. This dual-immunotherapy regimen is the first and only approved globally for neoadjuvant treatment of colon cancer, addressing a significant unmet clinical need and offering a new therapeutic option for patients in China.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251225:nNDL681Kfl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828474.EUR","LU2097828714.EUR","LU2328871848.SGD","BK1583","LU2242644610.SGD","HK0000165453.HKD","01911","LU0455707207.USD","BK1589","BK1161","LU2097828631.EUR","LU1969619763.USD","BK1147","LU2097828557.USD","LU2097828805.USD","LU2488822045.USD","LU0502904849.HKD","01801"],"gpt_icon":0},{"id":"2592941037","title":"Innovent Biologics Publishes Landmark Phase 3 Mazdutide Diabetes Trials in Nature","url":"https://stock-news.laohu8.com/highlight/detail?id=2592941037","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592941037?lang=en_us&edition=fundamental","pubTime":"2025-12-18 08:00","pubTimestamp":1766016043,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc. has announced the publication of results from two Phase 3 clinical studies  of mazdutide, a GLP-1/GCG dual receptor agonist, in Chinese adults with type 2 diabetes. The results were published as Accelerated Article Previews in Nature. Previously, the results of mazdutide’s Phase 3 weight loss clinical study  were published in The New England Journal of Medicine. Mazdutide is approved in China for glycemic control and weight management. Multiple additional studies and indication explorations for mazdutide are ongoing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire  on December 18, 2025, and is solely responsibl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL6l1K4R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1147","LU2488822045.USD","01911","LU0455707207.USD","LU2097828557.USD","LU2097828714.EUR","01801","BK1589","HK0000165453.HKD","LU2097828631.EUR","BK1161","LU2242644610.SGD","LU2097828474.EUR","LU2328871848.SGD","LU2097828805.USD","BK1583","LU1969619763.USD","LU0502904849.HKD"],"gpt_icon":0},{"id":"2590554083","title":"Innovent Biologics Reports Mazdutide Achieves Significant Weight Loss in Chinese Adolescents with Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2590554083","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590554083?lang=en_us&edition=fundamental","pubTime":"2025-12-12 08:00","pubTimestamp":1765497619,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc. has announced the results of a Phase 1b clinical study evaluating mazdutide, a dual GLP-1 and glucagon receptor agonist, in Chinese adolescents with obesity. The study met its primary endpoint, with participants receiving 4 mg and 6 mg doses of mazdutide achieving BMI reductions of 8.78% and 10.99%, and weight reductions of 7.72 kg and 8.65 kg, respectively, over 12 weeks. These outcomes were significantly greater than those observed in the placebo group. Mazdutide also showed favorable safety and tolerability, with no serious adverse events reported. Improvements were noted in multiple metabolic parameters. Based on these results, Innovent Biologics plans to initiate a Phase 3 registration clinical trial in adolescents with obesity or overweight in the near future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is fo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL2Zl9Bl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1147","LU1969619763.USD","BK1589","HK0000165453.HKD","LU2097828474.EUR","01911","LU2097828714.EUR","LU2328871848.SGD","BK1161","LU0455707207.USD","LU0502904849.HKD","LU2097828557.USD","LU2488822045.USD","BK1583","LU2242644610.SGD","LU2097828805.USD","01801","LU2097828631.EUR"],"gpt_icon":0},{"id":"2590373878","title":"Innovent Biologics Doses First Participant in Phase 1 Trial of Anti-IL-1RAP Antibody for Gout Flares","url":"https://stock-news.laohu8.com/highlight/detail?id=2590373878","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590373878?lang=en_us&edition=fundamental","pubTime":"2025-12-10 08:27","pubTimestamp":1765326446,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc. has announced the successful dosing of the first participant in a Phase 1 clinical trial for IBI3011, a recombinant anti-human Interleukin 1 Receptor Accessory Protein  monoclonal antibody. IBI3011 is the first anti-IL-1RAP monoclonal antibody developed in China targeting inflammatory and autoimmune diseases, and preclinical data indicate it can significantly suppress gout flares in acute gouty arthritis models. The current trial is a single ascending dose study designed to evaluate the safety, tolerability, and pharmacokinetics of IBI3011 in both healthy volunteers and patients with gout flares. Additionally, Innovent highlighted promising Phase 2 results for IBI128 , which were presented at APLAR 2025, demonstrating strong efficacy in reducing serum uric acid levels in patients with gout. The company plans to advance IBI128 to Phase 3 trials and continues to expand its pipeline for metabolic and autoimmune diseases.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL6WJy9c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801","LU2097828714.EUR","01911","BK1147","LU1969619763.USD","LU2097828474.EUR","HK0000165453.HKD","LU0502904849.HKD","BK1161","LU2097828631.EUR","LU2097828805.USD","LU2242644610.SGD","LU2097828557.USD","BK1589","LU0455707207.USD","LU2328871848.SGD","LU2488822045.USD","BK1583"],"gpt_icon":0},{"id":"2590362883","title":"Innovent Biologics' PECONDLE Achieves Phase 3 Success for Moderate-to-Severe Psoriasis","url":"https://stock-news.laohu8.com/highlight/detail?id=2590362883","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590362883?lang=en_us&edition=fundamental","pubTime":"2025-12-09 08:00","pubTimestamp":1765238427,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc. has announced that its self-developed recombinant anti-interleukin-23p19 subunit monoclonal antibody, PECONDLE , met both primary and key secondary efficacy endpoints in the Phase 3 CLEAR-2 study. The CLEAR-2 trial was a randomized withdrawal and retreatment study conducted in Chinese participants with moderate-to-severe plaque psoriasis. PECONDLE received market approval from the National Medical Products Administration  in November 2025 for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. The results of the Phase 3 study have already been announced.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original cont","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDLcdBYNS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","HK0000165453.HKD","LU0455707207.USD","LU2097828714.EUR","LU2242644610.SGD","LU2097828474.EUR","LU0502904849.HKD","01911","BK1583","LU2328871848.SGD","01801","LU2097828805.USD","LU2097828631.EUR","LU2488822045.USD","LU1969619763.USD","BK1161","LU2097828557.USD","BK1147"],"gpt_icon":0},{"id":"2589802568","title":"Innovent Biologics Unveils Promising Phase 1 Results for Trispecific Antibody IBI3003 in Relapsed Multiple Myeloma","url":"https://stock-news.laohu8.com/highlight/detail?id=2589802568","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589802568?lang=en_us&edition=fundamental","pubTime":"2025-12-08 09:03","pubTimestamp":1765155800,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc. announced initial results from the first-in-human Phase 1 clinical trial of IBI3003, a novel trispecific antibody targeting GPRC5D, BCMA, and CD3 for the treatment of relapsed or refractory multiple myeloma. The data were presented in an oral session at the 2025 American Society of Hematology  Annual Meeting. IBI3003 demonstrated favorable tolerability and a manageable safety profile, with encouraging efficacy signals observed, particularly in high-risk patients, including those with extramedullary disease or prior exposure to anti-BCMA and/or anti-GPRC5D therapies. The ongoing Phase 1/2 clinical trial  is evaluating the safety, tolerability, and efficacy of IBI3003 in China and Australia.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, inve","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL2LlFwX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01911","LU2242644610.SGD","BK1589","LU2328871848.SGD","LU2097828714.EUR","BK1147","01801","LU1969619763.USD","LU2097828474.EUR","LU2097828805.USD","LU2097828557.USD","HK0000165453.HKD","LU2488822045.USD","BK1161","LU0455707207.USD","LU0502904849.HKD","BK1583","LU2097828631.EUR"],"gpt_icon":0},{"id":"2589871464","title":"Innovent Biologics Wins NRDL Inclusion for Seven Innovative Drugs in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2589871464","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589871464?lang=en_us&edition=fundamental","pubTime":"2025-12-07 18:06","pubTimestamp":1765101984,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 07, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251207:nNDL9rqL8K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1589","LU0455707207.USD","LU1969619763.USD","LU2097828631.EUR","HK0000165453.HKD","LU2328871848.SGD","LU2097828805.USD","LU2097828474.EUR","BK1161","LU2097828714.EUR","LU2242644610.SGD","BK1147","01801","LU0502904849.HKD","LU2488822045.USD","LU2097828557.USD","01911"],"gpt_icon":0},{"id":"2589042853","title":"Innovent Biologics and Takeda Launch $11.4 Billion Global Oncology Partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2589042853","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589042853?lang=en_us&edition=fundamental","pubTime":"2025-12-05 07:39","pubTimestamp":1764891541,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc. has finalized a global strategic partnership with Takeda to accelerate the development and commercialization of next-generation immuno-oncology  and antibody-drug conjugate  therapies. The collaboration includes joint global development and U.S. co-commercialization of IBI363 , global rights outside Greater China for IBI343 , and an exclusive option for Takeda to license global rights to IBI3001  outside Greater China. Takeda will pay Innovent $1.2 billion upfront, including a $100 million equity investment, with total deal value reaching up to $11.4 billion through additional development, sales milestones, and potential royalties.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL9L5xZJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828631.EUR","BK1147","HK0000165453.HKD","LU2097828805.USD","LU2328871848.SGD","BK1161","LU1969619763.USD","LU2488822045.USD","LU2097828474.EUR","BK1583","LU0502904849.HKD","LU2097828557.USD","01911","LU2242644610.SGD","LU2097828714.EUR","LU0455707207.USD","01801","BK1589"],"gpt_icon":0},{"id":"1134728285","title":"10th Zhitong Capital Market Annual Conference Honors Excellence with 25 Awards Unveiled","url":"https://stock-news.laohu8.com/highlight/detail?id=1134728285","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134728285?lang=en_us&edition=fundamental","pubTime":"2025-12-03 19:38","pubTimestamp":1764761917,"startTime":"0","endTime":"0","summary":"On December 3, 2025, the \"10th Zhitong Capital Market Annual Conference & Listed Companies Awards Ceremony,\" jointly hosted by leading Hong Kong and U.S. stock information platform Zhitong Finance...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1719994722.HKD","LU1974910355.USD","IE00BQXX3F31.USD","LU2328871848.SGD","LU2249611893.SGD","LU0431992006.USD","BK1225","LU0488056044.USD","BK1137","02509","BK1096","BK1522","LU0499858602.USD","BK1229","00875","00960","09890","LU0164872284.USD","LU0261950470.USD","LU0072462343.USD","00020","LU0082770016.USD","02276","82020","BK1586","00826","01164","LU0231483743.USD","01907","00136","09639","02382","LU1861214812.USD","BK1221","02556","06100","09985","IE0009570106.USD","LU0588546209.SGD","02298","LU1951186391.HKD","LU2153591404.USD","LU2097828631.EUR","80992","09990","IE00BGHQDM52.EUR","LU0052756011.USD","LU0320764599.SGD","03800","LU0274383008.USD","LU0348735423.USD","LU0819123356.HKD","LU1813983027.USD","LU2242644610.SGD","BK1207","LU1115378108.SGD","BK1518","HK0000306685.HKD","LU1008478684.HKD","LU0269904917.USD","01119","00777","BK1142","BK1574","BK1168","LU2460026573.USD","BK1604","BK1596","00656","IE00BVYPNQ40.USD","LU0348767384.USD","BK1247","LU0214875030.USD","BK1564","LU0516423174.USD","BK1540","BK1595","01600","09860","BK1169","02331","LU0329678170.USD","SG9999015945.SGD","LU1770036033.HKD","02020","BK1515","HK0000306701.USD","IE00B0JY6N72.USD","IE00B29SXG58.USD","LU0359201612.USD","BK1148","02696","LU1981816686.USD","00666","02157","02190","LU0588545904.SGD","02533","LU0384037296.USD","BK1209","02565","02197","02506","IE0031814852.USD","LU1770034418.SGD","LU0054237671.USD","03681","BK1530","02453","HK0000252160.HKD","IE0008369823.USD","IE0032431581.USD","BK1125","BK1528","LU0828237510.HKD","LU0708995583.HKD","01530","09699","LU0229945570.USD","02121","00798","09911","LU1039395188.USD","01405","IE00B8HQ1Z84.USD","00460","LU0348827113.USD","02250","01939","LU0640798160.USD","02431","LU0211977185.USD","LU1868837722.USD","BK1618","LU1917777945.USD","LU0140636845.USD","LU0979878070.USD","00451","LU0417516571.SGD","LU0823426308.USD","LU1282649067.USD","06862","LU0572940350.SGD","LU0856984785.SGD","SG9999015952.SGD","BK1109","LU2008162690.USD","BK1524","BK1195","02392","BK1598","06618","02315","09923","00305","09956","LU0762540952.USD","LU0417516738.SGD","02590","BK1593","LU0456827905.SGD","LU0499858438.USD","LU0329678337.USD","06138","SG9999004220.SGD","09996","01520","LU2476274308.USD","BK1258","06186","LU0620787316.HKD","BK1516","02158","BK1154","LU2399975544.HKD","LU0593848301.USD","LU1046422090.SGD","01952","03680","BK1559","LU0314109678.HKD","01384","LU0326950275.SGD","BK1526","06919","BK1216","BK1188","BK1237","LU0165289439.USD","BK1155","BK1575","BK1609","HK0000252152.HKD","LU0469268626.HKD","BK1600","LU0737861699.HKD","LU0516422952.EUR","BK1550","01640","IE00BGV7N243.SGD","LU1497733631.SGD","LU0588545490.SGD","LU0650527681.SGD","LU0594300179.USD","LU1366334651.USD","00300","BK1544","LU1048588211.SGD","02889","00363","LU0264606111.USD","LU1282649810.SGD","81211","01117","01911","BK1552","BK1215","02273","BYDDY","00855","BK1591","IE00B031J352.USD","IE0003795394.USD","02469","LU0052750758.USD","09926","LU1808992512.USD","BK1224","00884","SGXZ86797644.SGD","LU0289960550.SGD","LU1102505929.USD","BK1253","LU1956131251.USD","LU0345775950.USD","SGXZ90724238.SGD","BK1193","LU0289961442.SGD","LU1634259557.SGD","01833","BK1605","06058","LU0164880469.USD","LU0251143458.SGD","BK1212","BK1583","BK1235","LU0456846285.SGD","IE0003851619.USD","LU0634319403.HKD","LU0702159699.USD","01809","IE00B031HY20.USD","02616","LU1226287792.SGD","00867","LU0048575426.USD","LU0588545730.USD","02171","BK1171","SG9999001226.SGD","BK1579","02380","LU2424517915.HKD","06855","09878","LU0880133367.SGD","01318","01458","BK1548","LU1497734951.SGD","LU2023250504.SGD","LU1807302812.USD","SG9999002463.SGD","BK1186","HYDD.SI","BK1606","LU1226288170.HKD","02650","06086","BK1144","BK1615","01070","BK1230","09877","02436","BK1585","BK1197","02411","IE00BMCWC346.EUR","LU1497733557.USD","IE00BYV24P56.USD","01877","06160","LU0039217434.USD","BK1594","IE00B5MMRT66.SGD","LU2663582299.SGD","06060","86618","03836","BK1095","03709","02419","BK1527","80020","LU2778985437.USD","BK1150","SG9999000475.SGD","LU3063872942.SGD","02018","01773","SG9999002828.SGD","BK1571","ANPDY","LU0043850808.USD","LU0048580855.USD","BK1587","LU0572939691.SGD","BK1175","LU0315178854.USD","LU0327786744.USD","01818","09690","BK1119","LU0348784397.USD","LU2125910500.SGD","SG9999006597.SGD","LU1188198961.HKD","HK0000320264.USD","02420","BK1200","SG9999001069.SGD","LU0251144936.SGD","02057","BK1131","BK1577","LU0505663152.USD","09660","LU2506952253.HKD","BK1519","LU0359201885.HKD","06913","LU1328615791.USD","BK1164","LU0516423091.SGD","LU1831875114.USD","LU1861219969.SGD","LU0348783233.USD","01276","02145","01519","LU0501845795.SGD","BK1219","SG9999000418.SGD","LU0516422440.USD","BK1523","00384","BK1126","BK1582","LU1794554557.SGD","LU2238339852.HKD","06996","LU0261947096.USD","02268","02595","BK1170","BK1589","BK1222","LU0828238088.HKD","02460","03896","LU1868837565.USD","BK1183","BK1239","00302","BK1228","03939","SG9999015978.USD","01762","LU1023057109.AUD","BK1610","02627","BK1560","LU2360107325.USD","02670","LU2153592121.USD","06613","LU1235295612.USD","BK1557","00003","BK1194","82331","01211","LU0011963245.USD","BK1549","BK1114","LU0516422366.SGD","LU1481107354.HKD","LU2294711713.HKD","SG9999001051.SGD","01783","BK1214","02488","09961","SG9999011746.SGD","LU0823038988.USD","06657","BK1233","LU0149721374.USD","IE0034224299.USD","LU2097828805.USD","LU0791590937.USD","LU0611395673.USD","SG9999002562.SGD","01739","IE00BZ08YT58.USD","BK1160","HK0000500386.USD","LU0067412154.USD","LU0823397103.USD","LU2543165471.USD","01880","LU0449509016.USD","BK1500","02167","BK1100","LU1226288253.USD","LU0345776255.USD","01440","BK1191","LU1166156734.SGD","02629","09919","LU0054450605.USD","IE00BQXX3C00.GBP","LU1152091168.USD","LU0072913022.USD","09927","LU2348774022.SGD","LU0531970944.HKD","LU1226287875.USD","IE00B0169L03.USD","LU0259732245.USD","BK1158","01471","LU0868486357.SGD","IE00BZ08YR35.GBP","BK1127","06821","BK1124","02498","06609","BK1240","LU1675838814.USD","06963","HK0000320223.HKD","LU2039709279.SGD","BK1257","02525","BK1556","LU1242518857.USD","LU0051755006.USD","LU1720050803.USD","LU0082770016.SGD","LU0511384066.AUD","BK1578","02279","LU2348773727.SGD","LU0048597586.USD","LU2097828557.USD","BK1542","BK1554","LU0819121731.USD","06683","LU0502904849.HKD","02177","BK1184","BK1504","LU0107464264.USD","LU2177674079.SGD","LU1960683339.HKD","00267","01585","09678","BK1136","LU0823039010.USD","BK1147","02886","00699","BK1227","LU0164939612.USD","SG9999001903.USD","00861","BK1178","BK1566","LU1224709979.USD","LU1993786604.SGD","00382","SG9999003461.SGD","00135","06677","01969","LU1242518931.SGD","BK1521","LU2045819591.USD","09955","LU2506951792.HKD","02551","LU1880383440.USD","LU0164865239.USD","LU1634259391.SGD","LU0531971595.HKD","LU0254981946.USD","LU0463099449.HKD","02105","SGXZ62798434.SGD","LU1522347837.USD","IE00BPRC5H50.USD","LU1211504680.USD","BK1132","IE00BVYPNP33.GBP","LU1303224171.USD","02155","BK1116","LU0871576103.HKD","SG9999001093.SGD","00512","BK1608","BK1220","BK1539","LU1226287529.USD","02100","BK1613","LU1868838027.USD","03145","02142","LU0831093199.SGD","BK1140","LU0315179316.USD","BK1134","LU0244354667.USD","00992","BK1509","02228","BK1198","01378","01735","02096","LU2298064838.USD","01093","LU2476274720.SGD","LU1880383366.USD","IE00B543WZ88.USD","LU0348766576.USD","BK1520","BK1590","LU0572944931.SGD","BK1151","LU0541502299.USD","LU0287142896.SGD","LU0543330566.HKD","BK1555","BK1104","002594","LU1267930227.SGD","BK1597","BK1139","BK1167","LU0049112450.USD","03658","IE00BQXX3D17.EUR","02150","IE00BZ08YS42.EUR","03677","BK1619","LU1366334578.USD","01448","03396","SG9999002950.SGD","LU1508157978.USD","02552","LU1939255532.USD","BK1141","BK1616","BK1617","BK1512","SG9999014674.SGD","BK1607","BK1128","LU0370786039.SGD","BK1143","LU0228659784.USD","BK1111","LU0561508036.HKD","06633","09992","BK1179","LU0594300419.USD","BK1531","SG9999000459.SGD","BK1161","02598","LU0509642566.USD","LU2488822045.USD","LU2357125470.USD","LU0605514214.HKD","02451","03738","BK1541","LU0417516902.SGD","LU0289739343.SGD","LU0173614495.USD","02400","LU0261950983.USD","LU0541501648.USD","LU0307460666.USD","01681","LU1152091754.HKD","LU0359202008.SGD","01177","06608","BK1592","LU0310800965.SGD","02256","09959","LU0348825331.USD","LU0865486749.SGD","06988","00999","LU0175139822.USD","LU0455707207.USD","LU0143863784.USD","IE00BD6J9T35.USD","LU0823426480.USD","LU1969619763.USD","LU0143863198.USD","LU0823414478.USD","02587","LU0823437842.USD","LU1328277881.USD","LU0449515922.USD","01651","LU0084288322.USD","03998","LU2449936058.SGD","BK1163","06069","SG9999015986.USD","IE00B8L5B284.USD","LU0128525689.USD","BK1189","BK1588","09880","03650","LU1102505762.USD","LU0823397285.USD","LU2106854487.HKD","BK1110","02511","09636","LU2097828474.EUR","02567","BK1502","LNNGY","LU0823414551.USD","LU2097828714.EUR","SG9999004311.SGD","HK0000165453.HKD","SG9999006514.SGD","02013","00017","LU1961090484.USD","LNVGY","LU0791591158.USD","BK1190","IE0008368742.USD","LU0737861772.HKD","BK1117","LU0540923850.HKD","01333","BK1553","LU0348805143.USD","02858","06090","06168","LU1251922891.USD"],"gpt_icon":1},{"id":"2586920270","title":"Innovent Biologics Wins China Approval for PECONDLE to Treat Plaque Psoriasis","url":"https://stock-news.laohu8.com/highlight/detail?id=2586920270","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586920270?lang=en_us&edition=fundamental","pubTime":"2025-11-28 16:45","pubTimestamp":1764319518,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc. has received regulatory approval from China's National Medical Products Administration  for PECONDLE , a recombinant anti-interleukin-23p19 subunit antibody, for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy. This approval marks PECONDLE as the first domestically developed IL-23p19 inhibitor in China for this indication. The approval was based on positive results from a Phase 3 registrational study, where the drug demonstrated significant improvement in clinical endpoints compared to placebo.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via IIS, the Issuer Inf","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nNDL3y02f2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828631.EUR","BK1583","LU1969619763.USD","LU0455707207.USD","HK0000165453.HKD","LU2097828557.USD","LU0502904849.HKD","BK1161","01801","BK1147","LU2097828805.USD","LU2242644610.SGD","BK1589","LU2328871848.SGD","LU2097828714.EUR","01911","LU2488822045.USD","LU2097828474.EUR"],"gpt_icon":0},{"id":"2586342860","title":"China NMPA Accepts Review of Mazdutide 9mg Application from Innovent Biologics","url":"https://stock-news.laohu8.com/highlight/detail?id=2586342860","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586342860?lang=en_us&edition=fundamental","pubTime":"2025-11-25 16:30","pubTimestamp":1764059437,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc. announced that the supplementary application for the 9mg dosage of mazdutide, an innovative dual GCG/GLP-1 receptor agonist, has been accepted for review by China's National Medical Products Administration  Center for Drug Evaluation. The application targets long-term weight management in adults with moderate to severe obesity. This regulatory review aims to address unmet clinical needs in China by providing a new and effective treatment option for obesity.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on November 25, 2025, and is solely ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL6zH4MR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801","LU0502904849.HKD","BK1583","LU0455707207.USD","LU1969619763.USD","LU2097828557.USD","LU2097828631.EUR","LU2097828805.USD","LU2488822045.USD","LU2097828474.EUR","LU2328871848.SGD","01911","LU2097828714.EUR","LU2242644610.SGD","BK1589","BK1161","HK0000165453.HKD","BK1147"],"gpt_icon":0},{"id":"2585145539","title":"Innovent Biologics Joins Hang Seng Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2585145539","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585145539?lang=en_us&edition=fundamental","pubTime":"2025-11-24 14:20","pubTimestamp":1763965207,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc. will be added to the Hang Seng Index following the Q3 2025 Hang Seng Index Series Quarterly Review. The inclusion reflects the international capital market's strong recognition of Innovent's value as a leading innovative biopharmaceutical company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire  on November 24, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL1g7S7n:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2242644610.SGD","LU2097828474.EUR","LU0455707207.USD","BK1147","BK1589","01911","LU2328871848.SGD","BK1161","LU2097828557.USD","BK1583","LU2097828631.EUR","01801","LU1969619763.USD","LU2097828714.EUR","LU2097828805.USD","LU2488822045.USD","HK0000165453.HKD","LU0502904849.HKD"],"gpt_icon":0},{"id":"2584726429","title":"Mazdutide Achieves 20% Weight Loss in Phase 3 Obesity Trial, Innovent Plans China NDA Submission","url":"https://stock-news.laohu8.com/highlight/detail?id=2584726429","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584726429?lang=en_us&edition=fundamental","pubTime":"2025-11-20 08:00","pubTimestamp":1763596822,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc. announced that its Phase 3 clinical trial of mazdutide, a dual glucagon /glucagon-like peptide-1  receptor agonist, in Chinese adults with obesity  met both its primary and all key secondary endpoints. Mazdutide 9 mg achieved up to 20.1% weight loss in obese adults without type 2 diabetes after one year of treatment using a 2-step dose titration. Innovent plans to submit a new drug application  for mazdutide 9 mg for weight management to the Center for Drug Evaluation  of China's National Medical Products Administration  in the near term. Clinical findings on mazdutide have already been published in international journals such as The New England Journal of Medicine, Nature Communications, Diabetes Care, and eClinicalMedicine, and have been presented at scientific conferences including those of the American Diabetes Association  and the European Association for the Study of Diabetes .","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nNDL7wxt6X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1147","LU2097828714.EUR","BK1161","LU1969619763.USD","LU2328871848.SGD","BK1583","LU0502904849.HKD","LU2488822045.USD","LU2097828557.USD","LU0455707207.USD","01801","HK0000165453.HKD","BK1589","LU2097828474.EUR","LU2097828805.USD","LU2097828631.EUR","LU2242644610.SGD","01911"],"gpt_icon":0},{"id":"2582810869","title":"Innovent Biologics Reports Positive Phase 1 Results for Hypertension siRNA Drug IBI3016","url":"https://stock-news.laohu8.com/highlight/detail?id=2582810869","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582810869?lang=en_us&edition=fundamental","pubTime":"2025-11-10 10:09","pubTimestamp":1762740559,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc., in collaboration with Sanegene Bio USA Inc., has announced preliminary results from a first-in-human Phase 1 clinical study of IBI3016 , an experimental small interfering RNA  medicine targeting angiotensinogen mRNA  for the treatment of hypertension. The results were presented at the 2025 American Heart Association  scientific sessions. According to the companies, IBI3016 demonstrated sustained and potent AGT mRNA suppression with preliminary evidence of antihypertensive efficacy following a single-dose subcutaneous administration. The Phase 1 data suggest the potential for biannual subcutaneous dosing for hypertension treatment. The companies plan to initiate the next phase of clinical development soon.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL69Hp6B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828714.EUR","LU2097828631.EUR","01911","LU2488822045.USD","LU1969619763.USD","BK1583","LU2097828805.USD","LU2242644610.SGD","BK1147","BK1589","LU2097828557.USD","LU0455707207.USD","LU0502904849.HKD","LU2097828474.EUR","01801","BK1161","HK0000165453.HKD","LU2328871848.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.chinarenaissance.com","stockEarnings":[{"period":"1week","weight":-0.132},{"period":"1month","weight":-0.0181},{"period":"3month","weight":-0.2815},{"period":"6month","weight":-0.2517},{"period":"1year","weight":0.5122},{"period":"ytd","weight":0.0508}],"compareEarnings":[{"period":"1week","weight":-0.0154},{"period":"1month","weight":0.0304},{"period":"3month","weight":0.0238},{"period":"6month","weight":0.0471},{"period":"1year","weight":0.3222},{"period":"ytd","weight":0.0372}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"China Renaissance Holdings Ltd is a holding company that is primarily engaged in providing investment banking and investment management services. The Company operates in four segments. Investment Banking segment provides early to late stage financial advisory and mergers and acquisitions advisory services, equity underwriting, sales, trading, brokerage, research services and structured financial services. Investment Management segment provides fund and asset management and manages its own investments in funds. China Renaissance (CR) Securities segment provides investment banking and asset management business. Others segment mainly includes wealth management business and investment and management of own funds.","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":0.111894},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.021376},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.031485},{"month":4,"riseRate":0.2,"avgChangeRate":-0.077146},{"month":5,"riseRate":0.2,"avgChangeRate":-0.049869},{"month":6,"riseRate":1,"avgChangeRate":0.143061},{"month":7,"riseRate":0.4,"avgChangeRate":0.051599},{"month":8,"riseRate":0.6,"avgChangeRate":0.100699},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.131486},{"month":10,"riseRate":0,"avgChangeRate":-0.130048},{"month":11,"riseRate":0.285714,"avgChangeRate":0.027229},{"month":12,"riseRate":0.428571,"avgChangeRate":-0.035994}],"exchange":"SEHK","name":"CR HOLDINGS","nameEN":"CR HOLDINGS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CR HOLDINGS(01911),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CR HOLDINGS(01911) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CR HOLDINGS,01911,CR HOLDINGS股票,CR HOLDINGS股票老虎,CR HOLDINGS股票老虎国际,CR HOLDINGS行情,CR HOLDINGS股票行情,CR HOLDINGS股价,CR HOLDINGS股市,CR HOLDINGS股票价格,CR HOLDINGS股票交易,CR HOLDINGS股票购买,CR HOLDINGS股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CR HOLDINGS(01911),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CR HOLDINGS(01911) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}